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Abstract
Background: Raynaud’s phenomenon is one of the first clinical manifestations observed in systemic sclerosis (SSc).
This microvasculature disorder affects mostly the digits in over 95% of SSc patients, significantly affecting their health-
related quality of life (HRQoL) and incurring higher hospital admissions and other healthcare costs. Exercise is known to
improve both micro- and macrovascular function – aerobic exercise and resistance training, separately or combined,
have been demonstrated to lead to significant vasculo-physiological improvements in conditions that present
vasculopathy. However, the effects of a combined exercise programme on microcirculation in SSc patients has yet to
be investigated. Therefore, the purpose of this study is to assess the effects of high-intensity interval training (HIIT)
combined with circuit resistance training on the microvascular function in the digital area of SSc patients.
Methods: This will be a randomised controlled, feasibility trial with two arms, wherein 30 patients with SSc in receipt
of medical treatment will be randomly assigned to usual care (medical treatment) or to a 12-week supervised exercise
programme. Patients in the exercise group will undertake two, 45-min sessions each week consisting of 30 min HIIT (30
s 100% peak power output/30 s passive recovery) on the arm crank ergometer and 15 min of upper body circuit
resistance training. Patients will be assessed before as well as at 3 and 6 months following randomisation. Primary
outcomes of the study will be recruitment and retention rate, intervention acceptability and adherence to the exercise
programme. Secondary outcomes include the digital area cutaneous microvascular function (laser Doppler fluximetry
combined with iontophoresis), physical fitness, functional ability, upper back transcutaneous oxygen tension, body
composition and quality of life (EQ-5D-5L). Selected interviews with a subsample of patients will be undertaken to
explore their experiences of having Raynaud’s phenomenon and the acceptability of the exercise intervention and
study procedures.
Discussion: Data from this study will be used to identify the feasibility of a combined exercise programme to be
implemented in SSc patients, the acceptability of the intervention and the study design, and to determine the effects
of exercise on the microvasculature. Overall, this study will provide sufficient data to inform and support a full
multicentre clinical trial.
Trial registration: ClinicalTrials.gov (NCT number): NCT03058887, February 23, 2017.
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feasibility studies
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Background
Systemic sclerosis (SSc) is an autoimmune connective
tissue disease characterised by tissue fibrosis and vascular
involvement. Vasculopathy is directly implicated in the
pathogenesis of SSc representing acute manifestations (e.g.
pulmonary arterial hypertension, digital ulcers). Raynaud’s
phenomenon (RP) is one of the first clinical manifestations
presented in SSc, with a 95% prevalence across patients.
RP precedes any other clinical symptoms of SSc and is due
to hypoxia in the extremities in response to cold. Evidence
suggests that endothelial injuries in conjunction with an
imbalance in the vascular tone trigger RP [1], which in turn
develops digital ischemia, a serious complication for
patients with SSc. Morbidity rates in patients with SSc due
to digital ischemia reach approximately 30% annually [2].
Patients with chronic digital ulcers develop irreversible
tissue loss [2], which usually requires hospitalisation for
iloprost infusion [3] lasting from 5 days to 3 weeks. Hospi-
talisation is a psychologically stressful procedure for the
patient, directly affecting their health-related quality of life
(HRQoL). The most common side effects of iloprost infu-
sion are headache, flushing of the skin, nausea, vomiting
and sweating. Amputation has been reported to occur in
one or more digits due to ischemia in 20.4% of patients
with SSc, 9.2% of which have multiple digit loss [4].
A recent review paper has aggregated the studies that
have examined the effects of exercise in SSc patients with
and without pulmonary involvement [5], summarising the
beneficial effects, including good exercise tolerance and
increased aerobic capacity [6–8], muscle strength [6, 9],
hand mobility, [10–12], functional ability in daily activities
[11] and increased HRQoL [10, 11]. However, most stud-
ies lacked reporting of the intensity of their exercise
programme and none examined the effects of exercise on
the vasculature. Therefore, it is important to explore the
feasibility of a training protocol that would be able to (1)
improve vascular function and potentially decrease the
frequency and severity of digital ischemia and ulcers, and
(2) have the potential to decrease the use of pharmaco-
logical agents. These agents are used to improve microcir-
culation with short-term (e.g. oedema, headaches, heart
palpitations, dizziness and constipation) and long-term
(e.g. heart dysfunction, increased cardiovascular risk) side
effects and financial cost implications.
High-intensity interval training (HIIT) has demonstrated
its efficacy in improving the endothelial function in the
macrovasculature compared to moderate intensity continu-
ous training in a range of clinical conditions with impaired
vascular function [12]. HIIT has been shown to improve
cardiorespiratory fitness, cardiovascular risk factors and
biomarkers associated with vascular function. A HIIT
protocol with short intervals (30 s exercise/30 s passive
recovery; no exercise during resting intervals) may elicit
more favourable patient-reported satisfaction/enjoyment
levels compared to other longer duration exercise protocols
[13]. In chronic heart failure patients, a short duration HIIT
protocol (30 s exercise/30 s passive recovery) was demon-
strated to be well tolerated, a preferred protocol with a
low perception of effort, greater patient comfort and with
a longer time spent at higher percentage of peak oxygen
uptake (VO2peak) than a longer duration HIIT protocol
with active recovery phases (low intensity exercise during
resting intervals) [13].
Resistance training (RT) alone has been demonstrated to
be effective in improving the endothelial vascular function
in obese [14] and type 2 diabetes mellitus patients [15]
where a vascular dysfunction is present in the pathophysi-
ology of these conditions. The intensity of the RT ranged
from 75 to 85% of one repetition maximum for 8 to
12 weeks (twice or thrice per week). However, a combined
exercise regime (aerobic and RT) has also shown signifi-
cant improvements in endothelial vascular function in a
range of clinical conditions. More specifically, Metsios et
al. [16] examined the effects of a combined exercise proto-
col in rheumatoid arthritis patients who performed a
6-month exercise intervention. Endothelial function was
assessed via laser Doppler fluximetry (LDF) imaging using
iontophoresis. The results indicated that an individualised
aerobic and strength training programme significantly im-
proves both micro- and macrovascular endothelial function
in patients with rheumatoid arthritis. Other studies that
have implemented a combined exercise protocol in chronic
heart failure [17] and type 2 diabetes mellitus patients [18]
have demonstrated a significant improvement in the
microvascular reactivity of the forearm conduit and resist-
ance vessels after an 8-week programme. Consequently, it
seems that either RT alone or a combined protocol are able
to improve endothelial vascular function.
To our knowledge, the feasibility of a combined HIIT
protocol with short intervals (30 s at 100% peak power out-
put and 30 s passive recovery) and a circuit RT programme
on SSc patients has not yet been examined. Moreover, the
efficacy of exercise on microcirculation in SSc patients con-
stitutes another unexplored element of SS. Therefore, the
primary aim of our study would be to investigate the feasi-
bility of exercise in patients with SSc and the secondary
aim is to explore the effects of exercise on microcirculation.
Our study objectives are (1) to estimate the rates of recruit-
ment and retention for a future definitive trial of a 12-week
supervised exercise programme for SSc patients; (2) to esti-
mate the rates of attendance to and compliance with the
supervised exercise programme; (3) to assess the tolerance,
acceptability and enjoyment levels of the training protocol;
(4) to investigate the effects of exercise on microvascular
reactivity in the digital area; (5) to identify and quantify the
training dose that may induce microcirculatory improve-
ments in SSc patients; (6) to assess the effects of exercise
on HRQoL of SSc patients measured through generic
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questionnaires and interviews; and (7) to conduct
post-intervention interviews with patients to explore indi-
vidual’s experiences of the study’s procedures and exercise
programme.
Methods/Design
Study design
The FESS (Feasibility of Exercise in Systemic Sclerosis pa-
tients) study is a mixed methods feasibility study involving
a randomised controlled trial. Thirty patients with SSc re-
ceiving usual care (e.g. medical treatment) will be randomly
assigned (via block randomisation remotely by the study
chief investigator) to either an exercise group (12-week su-
pervised exercise programme) or to a control group being
in receipt only of the usual care. Patients will be followed
for 6 months following randomisation (Fig. 1). It is not
feasible to perform masking of patients or study investiga-
tors regarding the allocated treatments due to limited
resources. The study is being run at Sheffield Hallam
University in collaboration with the Royal Hallamshire
Hospital (Sheffield Teaching Hospitals, NHS, UK). The
study’s protocol and registration have been published in
ClinicalTrials.gov (NCT number: NCT03058887).
This study started in February 2017 and is due to be
completed by May 2018. The trial is sponsored by the
Vice Chancellor’s Fellowship award of Sheffield Hallam
University, and ethical approval was granted by the NHS
Health Research Authority, London Committee (16/LO/
0811), which allows ethical permission across Sheffield
Hallam University and Royal Hallamshire Hospital
(Sheffield Teaching Hospitals).
Recruitment of participants
Patients conforming to the eligibility criteria will be re-
cruited from the Rheumatology Department of the Royal
Hallamshire Hospital in Sheffield or will be self-referred
by seeing a poster in this location, through responding
to a public announcement, or after being notified of the
study via word of mouth. Patients recruited via hospital
clinics will be invited for participation through an
STUDY PERIOD
Enrolment Allocation Post-allocation
TIMEPOINT** -t1 0
Start of 
Treatment
3 months 
follow up
6 months 
follow up
ENROLMENT:
Eligibility and 
medical screen X
Informed consent X
Allocation X
INTERVENTIONS:
[A-Exercise and 
usual care]
[B-Usual care]
ASSESSMENTS:
Age and Gender
X
Body composition 
analysis
X X X
Blood pressure
X X X
EQ-5D-5L
X X X
Micro-vascular 
function
X X X
Functional ability
X X X
Peak oxygen 
uptake test
X X
Transcutaneous 
oxygen tension
X X
Qualitative 
Assessment 
(interviews)
X
Fig. 1 Study design
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invitation letter (including the contact details of a research
team member) accompanied by a patient information
sheet. Patients who express an interest (calling or posting
back) will be contacted by the research team to confirm
their eligibility, addressing any inquiries regarding the
study and arranging the first visit. Clinical care will not be
affected for those not wishing to take part in the study nor
those who decide to withdraw from the study.
The first visit will take place at the Centre for Sports
and Exercise Science at Sheffield Hallam University
laboratories, where the patient will be given further
details of the study procedures and will be asked to sign
a consent form to participate in the research study.
Afterwards, patients will be habituated with the trial
processes and will complete the baseline assessments.
Eligibility criteria
Patients eligible for the trial must comply with all of the
following at randomisation:
Inclusion criteria
➢ Patients diagnosed with limited cutaneous systemic
sclerosis according to the 2013 ACR/EULAR criteria
experiencing RP
➢ Men or women aged 18–80 years old
➢ Disease duration between 1 and 10 years
➢ Patients should be able to perform exercise
Exclusion criteria
➢ Patients with advanced pulmonary arterial
hypertension or interstitial lung disease
➢ Patients diagnosed with another inflammatory
condition
➢ Patients presenting myositis with proximal muscle
weakness
➢ Patients with New York Heart Association class 3
or 4
➢ Current smokers or people who stopped smoking
within 4 weeks of health screening
➢ Women who are currently pregnant
Withdrawals
Patients will be considered as withdrawn from the
research trial if they request to leave the trial, if they are
lost to follow-up or if they die before completing the
6-month follow-up.
Baseline measurements
At Visit 1, following the provision of written informed
consent and the confirmation of eligibility (which will
include a medical examination), the following baseline
measurements will be recorded:
 Demographic data, including age, sex and
socioeconomic status
 Clinical history, including incident or recurrent RP,
duration of disease, duration of RP attacks, current
medications, height, weight, body composition
(percentage body fat and lean muscle mass)
 Baseline exercise history
 HRQoL questionnaires: EQ-5D-5L [19] and RP
diary and condition score [20]
 Cutaneous microvascular function using LDF
combined with the iontophoresis technique in
the reference finger [21, 22]
 Functional capacity using the 6-minute walking
test [23]
 VO2peak will be performed on an arm-crank
ergometer
Exercise intervention
The exercise group will undertake twice weekly supervised
exercise sessions at the Centre of Sport and Exercise
Science at Sheffield Hallam University for 12 weeks (total
of 24 sessions). The weekly training structure and the train-
ing hours will be flexible to work around patients’ commit-
ments, although sessions in two consecutive days will be
avoided to allow sufficient recovery between sessions. The
duration of the exercise intervention is based upon
evidence reporting that an average training dose–response
of 12 weeks significantly improves the macrovasculature in
several disease states [12]. A maximum of 14 weeks will be
allowed for the patients to complete the 24 sessions, to
allow for missed sessions due to, for example, illness or
holiday.
Each session will comprise of a 5-min warm-up
period (involving light aerobic exercise and gentle
range of motion exercises). This will be followed by
an arm-cranking HIIT for 30 s at 100% of peak power
output interspersed by 30 s passive recovery for a
total of 30 min. The HIIT protocol will be combined
with RT lasting for a total of 15 min. RT will consist
of an upper body circuit training (five exercises) for
three circuits. The intensity will be at 75–80% of one
repetition maximum performing 10 repetitions of
each exercise interspersed by 20–30 s to allow for
safe movement between exercises. The recovery
period between circuits will last 2–3 min. Following
each exercise session, patients will undertake a 5 min
cool-down period, involving upper-limb light intensity
aerobic exercise and some light stretching. Patients
will wear heart rate (HR) monitors throughout the
exercise sessions. HR and the rating of perceived
exertion (RPE) will be assessed at regular intervals
throughout the supervised exercise session. The whole
duration of each exercise session will be approxi-
mately 45 min.
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Clinical management
All the patients in both studies will continue receiving
their standard medical treatment, i.e. calcium channel
blockers (nifedipine, sildenafil), and will be reviewed in
the clinic as often as is deemed clinically necessary. More-
over, in case of adverse events or worsening of symptoms
due to exercise or patients request, patients will be
withdrawn from the study for health and safety reasons.
Data management
The study will adhere to the Data Protection Act (1998).
Data from this study will be anonymised and stored in
password-protected computer systems accessible only by
the members of the research team in order to guarantee
confidentiality to patients. Paper forms will be stored in
locked filing cabinets. All data documents will be kept in a
secured and continuously monitored building where the
project will be conducted (Collegiate Hall, Collegiate
Crescent, Sheffield Hallam University). All study materials
will remain in this location for data entry and storage.
Double data entry will be implemented to ensure validity
and data quality. Participant names will not be used to
identify any data. Instead, patients will be assigned a study
identification number in order to anonymise their
information.
Data will all be anonymised according to the NHS
Code of Confidentiality and GMC Good Medical
Practice, while publications will not contain identifiable
personal data. Furthermore, only research team mem-
bers will have access to personal patient data during the
project, while data will be analysed locally by the study’s
statistician. Data will be kept for a 10-year period follow-
ing the study completion to allow the study team to
re-analyse it in case of the development of a new
method of analysis and for the data to be used for the
development of a future definitive RCT.
Safety monitoring
We will record all serious adverse events (as defined
below), as well as all non-serious adverse events that are
deemed to be related to participation in the research,
during the period between the provision of informed
consent through to 6 months after randomisation.
Serious adverse events are defined as any untoward
medical occurrence that either results in death, is
life-threatening (i.e. the patient is at risk of death at the
time of the event occurring), requires unplanned admis-
sions to emergency hospitalisations or prolonged hospital-
isation (deemed to be where a patient’s stay is longer than
expected, e.g. patient is operated on as a day case but
remains in hospital overnight), results in persistent or
significant disability or incapacitation, or results in a
congenital abnormality or birth defect.
A non-serious event in the context of this trial will be
any untoward medical occurrence to the participant that
is related to the patients’ involvement in the study but
does not fulfill any of the serious adverse event criteria.
Study investigators will be responsible for recording ad-
verse events and for determining the seriousness, severity,
causality and expectedness of any such events. The Chief
Investigator (MK) and a delegated clinician (MA) will then
be responsible for reviewing all adverse events and
confirming that they have been appropriately classified.
A serious adverse event will be reported to the Research
Ethics Committee and Sponsor where, in the opinion of
the Chief Investigator and the delegated clinician, the
event was related to the administration of a research
procedure or resulted in death regardless of relatedness.
Patients will be asked to contact the study team to inform
them about adverse events if and when they occur. Study
investigators will also question patients about the occur-
rence of adverse events during each participant study visit.
Outcome measures
The timeline for the outcome measures will be the base-
line measurements, and the 3- and 6-month follow-ups
after randomisation.
Feasibility outcomes
The primary aim of this study is acceptability and feasibil-
ity of procedures for recruitment, allocation, measurement
and retention as well as the adherence and enjoyment
levels of the exercise programme. Recruitment rates will
be assessed as the rate of invited patients who are eligible
and consenting and will be reported in a CONSORT
(Consolidated Standards of Reporting Trials) patient flow-
chart. Suitability of measurement procedures will be
assessed via interviews and reasons for missing data. Rea-
sons for dropouts will be used to evaluate the acceptability
of allocation procedures and exercise programme. The ac-
ceptability of the exercise programme will also be assessed
through questionnaires relevant to exercise task
self-efficacy, intentions for engagement to exercise, enjoy-
ment levels of exercise and the affect during exercise, and
the physiological stress of exercise monitored by HR and
RPE. The safety of exercise will be evaluated by the drop-
out number from the exercise group, and the number and
type of adverse events.
Enjoyment and tolerance of exercise
The feasibility and the perceived enjoyment of HIIT and
RT will be assessed through measures that will interpret
patients’ perception regarding the (1) exercise intensity,
(2) the affect, (3) the exercise task self-efficacy, (4) the
intentions and (5) the enjoyment. The above data will be
collected at the first and last exercise session each
month in order to examine several time points during
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the exercise intervention. Specifically, the questionnaires
will be administered at the 1st, 8th, 9th, 16th, 17th and
24th exercise sessions.
Exercise intensity
The RPE will be measured during exercise through a
20-point Borg scale [24] when 2.5%, 8.2%, 42.5%, 48.2%,
92.5% and 98.2% of the exercise programme is completed.
These time points have been chosen to incorporate both
interval and recovery periods during HIIT. In the RT, the
time points will be straight after the completion of each
exercise. The 20-point Borg scale ranges from 6 to 20 with
anchors ranging from ‘No exertion at all’ (0) to ‘Maximal
exertion’ [20]. Apart from measurement at the specified
time points during exercise, the RPE will be measured
pre- and post-exercise as well as 10 min after the exercise
session. Participant’s HR will also be recorded using Polar
HR monitors at the same time points as the RPE.
Affective valence
The one-item Feeling scale [25] will be used to measure
the general affective valence (e.g. pleasure and displeas-
ure) during the exercise session at the same time points
as the RPE (Additional file 1). At the beginning of the
first exercise session, patients will be provided with the
following instructions: “Experiencing alterations in your
mood is very common while performing exercise. The
sense of pleasure or displeasure varies among individuals
during the exercise; in addition, feelings may fluctuate
across time. So the answers might feel good and bad a
number of times during exercise, when you will be asked
to express your feelings using the scale below”. The feel-
ing scale is scored on an 11-point bipolar scale ranging
from − 5 to + 5. Seven anchors are provided ranging
from ‘Very good’ (+ 5) to ‘Very bad’ (− 5).
Exercise task self-efficacy
Patient’s confidence in their ability to repeat the exercise
session that they will just have completed will be assessed
only after the first exercise session at 20-min post-exercise
using a three-item measure (Additional file 2). Each ques-
tion will include the same introductory theme, “How
confident are you that you can…”. The three-items will be
(1) “… perform one bout of exercise a week for the next 4
weeks that is just like the one you completed today?”, (2)
“… perform two bouts of exercise a week for the next 4
weeks that is just like the one you completed today?” and(
3) “… perform three bouts of exercise a week for the next
4 weeks that is just like the one you completed today?”.
The scale score will vary from 0% (Not at all) to 100%
(Extremely confident) in 10% increments. The specificity
of the three items measure is formed and adapted accord-
ing to Jung et al. [26].
Intentions
Patient’s intentions to engage in the exercise session over
the next month will be measured utilising a two-item
measure (Additional file 3) at the 1st, 9th and 17th exercise
session, 20-min post-exercise [26]. Particularly, patients
will be asked “Please rate the extent to which you agree
with the following statements (1) ‘I intend to engage in the
type of exercise I performed today at least 2 times per week
during the next month’ and (2) ‘I intend to engage in the
type of exercise I performed today at least 3 times per week
during the next month’”. Answers will be scored on a
7-point rating scale with anchors ranging from ‘Very un-
likely’ [1] to ‘Very likely’ [7]. The two items will be analysed
individually.
Enjoyment
Patient’s enjoyment of the assessed exercise sessions will
be examined using a modified version of the Physical
Activity Enjoyment Scale [27] 20-min post-exercise. This
18-item measure is scored on a 7-point bipolar scale
(Additional file 4). Example items are “I find it energising/
I find it tiring” and “it’s very pleasant/it’s very unpleasant”.
The original measure is amended by erasing one of the 18
items that is irrelevant due to the time point that will be
measured (“I am absorbed in the activity/I am not at all
absorbed in the activity”). Moreover, the original Physical
Activity Enjoyment Scale instructions are amended from
“Please rate how you feel AT THE MOMENT about the
physical activity you have been doing” to “Please rate how
you feel about the exercise you just completed”. Both
modifications were made to reflect the correct time point
at which the questions/questionnaire will be administered
(20-min post-exercise).
Patient experiences for study procedures
We aim to undertake an in-depth exploration of the pa-
tients’ study experience in a subsample of six patients
from each group (exercise and control group). Inter-
views lasting between 30 and 35 min will take place 3
months after randomisation for both groups.
We aim to explore (1) patients’ experiences of RP; (2)
experiences of treatment and advice received pre FESS
trial; (3) participant’s preference for trial allocation (exer-
cise or control group); (4) experiences of study participa-
tion in both the exercise intervention group and control
group; and (5) participant’s acceptability of the exercise
intervention and study procedures.
We will adopt a constructivist approach [28], which
recognises the individual and personal nature of a
patient’s exercise experiences both before and during the
trial. Semi-structured face-to-face in-depth interviews
will be conducted at the Centre for Sports and Exercise
Science at Sheffield Hallam University in a comfortable
and private room. Interviews will be recorded and then
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transcribed verbatim, and will then be analysed themat-
ically by using framework analysis (familiarisation, iden-
tifying a thematic framework, indexing, charting and
mapping).
Sample and recruitment
Six and six patients from exercise and control group,
respectively, will be recruited using purposive sampling
(mixture of sexes, younger and older patients from exer-
cise and control group).
Secondary outcomes
Digital cutaneous microvascular function
Iontophoresis Microvascular assessments using LDF
and iontophoresis (as described in the literature; [22]) will
be performed in a temperature-controlled room (22–24 °
C). LDF electrodes will be attached to the dorsal aspect of
the reference fingers for acetylcholine (ACh) and sodium
nitroprusside (SNP) administration. These will be used as
indicators of the changes occurring in the endothelial
(dependent and independent) vasodilatory function. HR
(Sports Tester, Polar, Finland) and blood pressure of the
brachial artery (left arm; Dinamap Dash 2500, GE Health-
care, USA) will be monitored at 5-min intervals through-
out the protocol. The two drug delivery electrodes (PF383;
Perimed AB, Jarfalla, Sweden) will be positioned over the
healthy-looking skin, approximately 4 cm apart with one
containing 100 μL of 1% ACh (Miochol-E, Novartis, Stein)
and the other 80 μL of 1% SNP (Nitroprussiat, Rotta-
pharm). A battery-powered iontophoresis controller (Peri-
Iont PF382b; Perimed AB) will be used to provide the
charge needed for ACh and SNP delivery. A 4 min stable
recording of baseline flux will be followed by administra-
tion of the two agents according to the following protocol:
0.2 mA for 10 s (i.e. 2 mC), 0.2 mA for 15 s (i.e. 3 mC),
0.2 mA for 20 s (i.e. 4 mC), and 0.3 mA for 20 s (i.e. 6
mC), occurring between 4-min intervals [21, 22]. To
obtain an index of skin blood flow, cutaneous red cell flux
will be measured by placing an iontophoresis laser
Doppler probe (PF481–1; Perimed AB), connected to a
laser Doppler fluximeter (PF5001; Perimed AB).
Peak oxygen uptake test During the cardiopulmonary
tests, gas exchange will be collected and analysed by an
online breath-by-breath analysis system (Ultima™, Med-
ical Graphics, UK). The gas analyser will be calibrated
before each test according to the manufacturer’s calibra-
tion guidelines. HR breathing frequency, tidal volume,
minute ventilation, VO2 and volume of exhaled carbon
dioxide, and their ratios, as well as the respiratory ex-
change ratio, will be displayed on a monitor (Breeze-
Suite, MGC Diagnostics, USA) on a breath-by-breath
analysis. HR will be continuously monitored using a
Polar HR monitor (Polar FS1, Polar Electro, Kemple,
Finland) and blood pressure will be assessed by the
researcher using a manual sphygmomanometer (Dura-
Shock DS54, Welch Allyn, USA) and a stethoscope (Litt-
man Classic II, 3 M, USA). The RPE will be recorded
during the last 10 s of every minute during the exercise
test until volitional exhaustion using Borg’s scale [24]
with 6–20 points. Peak power output and test duration
will be measured in both tests. VO2peak will be defined
as the average oxygen consumption recorded from
expiratory samples during the final 30 s of exercise.
Arm crank ergometer protocol The arm crank ergom-
eter will be adjusted to ensure alignment between the er-
gometer’s crankshaft and the centre of the glenohumeral
joint. The patient’s sitting position will also ensure that
the elbows are slightly bent when the arm is out-
stretched and will be instructed to maintain their feet
flat on the floor at all times. Due to different power cap-
abilities, two different protocols will be instructed for
men and women. Men will commence at a workload of
40 W and women at 20 W. In both protocols, the crank
rate will be maintained at 70 rev min− 1 [29] and the lin-
ear ramp increments will be increased by 1 W/6 s and
1 W/10 s for men and women, respectively [30]. The test
will commence with 2 min resting and 2 min of
warm-up unloaded. A RPE of 18 or above and/or the
inability to maintain a crank rate above 60 rev min–1, or
if any contraindication signs emerge [31] will result in
the termination of the test. Following termination of the
exercise part of the test, an unloaded exercise will be
performed for 2–3 min allowing an active cool down.
Transcutaneous oxygen pressure (TcpO2)
TcpO2 measurements will be performed during the car-
diorespiratory tests using sensors that will be
non-invasively attached to the skin and allow to heat.
The sensors induce skin blood capillary dilatation
through heat, which increases the blood flow and results
in oxygen diffusion through the skin to the sensor. The
sensor measures TcpO2 values inwardly through an elec-
trochemical process.
Measurements will be performed using the TINA
TCM400 TcpO2 device (Radiometer, Copenhagen,
Denmark). The temperature of the probe will be set to
44.5 °C to allow maximal skin vasodilation, thereby de-
creasing the arterial-to-skin surface oxygen pressure gra-
dient. Before the exercise test, 15–20 min will be
allowed with the probe attached to the skin for stabilisa-
tion of TcpO2 value. Following the test, the TcpO2 values
will be automatically corrected according to a
temperature of 37 °C by the TINA device. The electrode
will be placed slightly below the right scapula on the
back away from any bone.
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Fixation rings will be used to hold the probe attached
to the skin and this will be filled with two small drops of
contact fluid before attachment to the sensor. The fluid
will then be heated causing the subsequent dilatation of
the skin. The raw values of the patient’s oxygen perfu-
sion will be defined as previously described in
Wasilewski et al. [32].
Health-related quality of life (HRQoL)
EQ-5D-5L questionnaire The EQ-5D-5L questionnaire
will measure the main outcome to assess the patients’
HRQoL throughout the study (baseline, 3- and 6-month
follow-up). The EQ-5D-5L is a generic measure of health
status, where health is characterised by five dimensions
(mobility, self-care, ability to undertake usual activities,
pain, anxiety/depression) [19]. Patients will be asked to de-
scribe their level of health on each dimension using one of
five levels, namely no problems, slight problems, moderate
problems, severe problems or extreme problems. To
evaluate the EQ-5D-5L outcome in the overall pre- and
post-exercise intervention we will calculate the quality-ad-
justed life years (a metric used in cost-utility analysis that
combines length and quality of life in a single parameter;
[33]). We will also report digital ulcers, hospitalisation for
iloprost infusion and digital amputations.
Functional ability test The functional ability will be
assessed through a 6-minute walking test. Although this
test lacks organ specificity in SSc, it can provide a valuable
outcome parameter and, thus, is suggested as a regular
assessment in this clinical condition [23]. Patients will be
instructed to walk as far as possible back and forth on a
10 m corridor for 6 minutes. They will also be instructed
to slow down, stop and/or rest as necessary if they experi-
ence breathlessness or become exhausted, but to resume
walking as soon as they feel able to. The laps and the total
walking distance will be recorded on a worksheet.
Statistical analysis
The sample size for a feasibility study should be adequate
to estimate the critical metrics needed to assess the feasi-
bility of conducting the definitive study, with sufficient
precision [34]. The critical metrics are the consent rate
(i.e. the proportion of eligible patients who consent to par-
ticipate and be randomised), improvement in microcircu-
lation and quality of life as well as compliance with
treatment, and attrition rates. Fifteen patients in each
group (n = 30 in total) will provide a sufficiently precise
(within 15 percentage points for a 90% confidence inter-
val) estimate of the proportion willing to be randomised,
assuming 35–40% intention to be randomised.
The SPSS software (version 23, IBM SPSS, New York,
USA) will be used to enter quantitative data and
cleaning the data and to carry out missing values imput-
ation and statistical analysis. The descriptive statistics,
including mean and standard deviation, will be pre-
sented for basic demographics and primary and second-
ary outcomes of the patients in intervention and control
groups. For categorical data, the χ2 test will be used to
infer on the significant association. Independent and
paired samples t tests will be used to account for the
changes upon the primary and secondary outcomes
within the group at pre- and post-exercise intervention
but also between the two groups. Kolmogorov–Smirnov
and Shapiro–Wilk tests will be used to test the normal
distribution of the dependent variable and Levene’s test
will be used to test the homogeneity of variances. Pear-
son’s r will test any relations and interactions between
our variables. The qualitative analysis will be performed
using framework analysis [35], aiming to describe indi-
viduals’ experiences of exercise, searching for common,
recurrent patterns but also exploring participant experi-
ences that might explain behaviour and improve advice
and services in the future. Data saturation will be
achieved when similar themes arise repeatedly and no
new themes arise in the interview.
Discussion
Digital ischemia is a direct result of RP in SSc patients
that adversely affects their HRQoL. The number of inci-
dents that require hospitalisation and, occasionally,
digital amputation is not negligible (30%) [2]. There is
strong evidence from a wide range of clinical conditions
in which vascular disease plays a leading role in their
pathophysiology, that exercise, and more specifically
HIIT and RT, are able to improve the endothelial vascu-
lar function and, thus, to increase macro- and microcir-
culation. Based on that evidence, we will attempt to
implement a combined exercise protocol, primarily
assessing its feasibility and, secondarily, its efficacy on
vascular tone. The feasibility study will provide import-
ant evidence about the effectiveness of supervised exer-
cise training as a complementary treatment to the usual
care (e.g. medical treatment) for improving microcircula-
tion in the digital area, physical fitness, functional ability
and HRQoL in SSc patients. The findings will inform a
future definitive multicenter randomised controlled trial
with a larger sample size. We acknowledge that our sam-
ple size might be a limitation for the current study but
we need to stress that FESS is a feasibility study in a
novel area and we will strictly adhere to the pre-defined
eligibility criteria to present a consistent and reprodu-
cible outcome. Moreover, the ratio between women and
men is uneven; however, the women to men ratio in
those with SSc is estimated to 5.2:1 in northeast England
[36]. Overall, the study is expected to provide valuable
evidence for future research with SSc patients.
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Trial status
Recruitment started in January 2018 and is ongoing.
Additional files
Additional file 1: Feeling scale. (DOCX 35 kb)
Additional file 2: Exercise task self-efficacy. (DOCX 37 kb)
Additional file 3: Intentions for engagement to exercise. (DOCX 34 kb)
Additional file 4: Physical activity enjoyment scale. (DOCX 44 kb)
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